Korea FDA Rebuts Reports Of Compulsory Licensing For Roche's Tamiflu
This article was originally published in The Pink Sheet Daily
Though policy would allow the government to ignore originator patents in an emergency, "Our basic stance remains unchanged for now," KFDA says; drug maker and ingredient supplier are standing by.
You may also be interested in...
SEOUL - Alarmed over the deaths of two South Koreans over the weekend infected with the A/H1N1 virus and over the rising number of people who have fallen victim to the pandemic, the government is moving to have the H1N1 test covered by the national health insurance system
SEOUL - South Korean pharmaceutical company Green Cross recently started "test production" of its own A/H1N1 flu vaccine, after receiving a virus strain from the UK's National Institution for Biological Standards and Control and from the Centers for Disease Control and Prevention of the U.S
SEOUL - Alarmed by the rising number of people infected with the H1N1 virus in neighboring Japan, and in Korea, the South Korean government has signed contracts recently to secure more of Roche's Tamiflu (oseltamivir) and GlaxoSmithKline's Relenza (zanamivir)